Price: $33.9700
$-0.18
-0.527%
|
Day's High:
| $34.44
| Week Perf:
| -1.96 %
|
Day's Low: |
$ 33.90 |
30 Day Perf: |
-12.9 % |
Volume (M): |
119 |
52 Wk High: |
$ 45.21 |
Volume (M$): |
$ 4,029 |
52 Wk Avg: |
$38.59 |
Open: |
$34.26 |
52 Wk Low: |
$31.86 |
|
|
Market Capitalization (Millions $) |
2,230 |
Shares
Outstanding (Millions) |
66 |
Employees |
1,429 |
Revenues (TTM) (Millions $) |
566 |
Net Income (TTM) (Millions $) |
-244 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
31 |
Galapagos Nv
Galapagos NV is a biotechnology company headquartered in Mechelen, Belgium with additional offices and research facilities in the United States and Europe. The company was founded in 1999 by Onno van de Stolpe, Rudi Pauwels, and Katrine Bosley, and has since grown into a major player in the development of innovative medicines based on new biological insights.
Galapagos NV specializes in the discovery and development of small molecule and antibody drugs designed to treat inflammatory and fibrotic diseases, as well as cancer. The company is focused on developing drugs that target specific biological pathways and mechanisms, including protein kinases, G-protein-coupled receptors, and fibroblast growth factors.
Galapagos NV operates through three main business units: Research, Development, and Services. The Research unit focuses on drug discovery, using innovative screening techniques and collaboration with academic and industry partners to identify new drug targets and lead compounds. The Development unit manages clinical trials and regulatory approval of new drugs, while the Services unit provides contract research and development services to third-party clients.
The company's pipeline includes several promising drug candidates in various stages of development. These include filgotinib, a selective JAK1 inhibitor currently in phase 3 trials for rheumatoid arthritis, Crohn's disease, and other inflammatory diseases; ziritaxestat (GLPG1690), an autotaxin inhibitor in phase 3 trials for idiopathic pulmonary fibrosis; and MOR106, an anti-IL-17 antibody in phase 2 trials for atopic dermatitis.
Galapagos NV is also known for its proprietary drug discovery platform, which incorporates genetics, chemistry, and biology to identify new drug targets and lead compounds. The company's platform includes several technologies, including target discovery, drug screening, and target validation, as well as a large and diverse library of compounds for drug optimization.
In addition to its drug discovery efforts, Galapagos NV is committed to sustainability and environmental stewardship. The company has implemented several initiatives to reduce its carbon footprint and operate in an environmentally responsible manner, including the use of renewable energy in its facilities and support for biodiversity conservation initiatives in the Galapagos Islands.
Overall, Galapagos NV is a leading biotechnology company that is dedicated to innovative drug development and sustainability. With its strong pipeline of drug candidates, proprietary drug discovery platform, and commitment to environmental responsibility, the company is well-positioned to continue to make important contributions to the healthcare and biotechnology industries.
Company Address: Generaal De Wittelaan L11 A3 Mechelen 2800
Company Phone Number: Stock Exchange / Ticker: NASDAQ GLPG
GLPG is expected to report next financial results on March 22, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
-3.72 $ |
Revenues (TTM) |
8.62 $
|
Cash Flow (TTM) |
- |
Cash |
8.67 $
|
Book Value |
43.09 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.72 $
|
Revenues (TTM) |
8.62 $ |
Cash Flow (TTM) |
- |
Cash |
8.67 $
|
Book Value |
43.09 $ |
Dividend (TTM) |
0 $ |
|
|
|
|